BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:BL-M11D1 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of BL-M11D1\, from ClinicalTrials.gov estima
 tes.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05924750-2893@assetmemo.bio
DTSTAMP:20261121T005826Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:BL-M11D1: Phase 1 readout est. (NCT05924750)
DESCRIPTION:BL-M11D1\, phase 1\, Acute Myeloid Leukemia.\nStudy: A Study of
  BL-M11D1 in Patients With Relapsed/Refractory Acute Myeloid Leukemia\nEst
 imated primary completion: December 2026. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/bl-m11d1#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT05924750
URL:https://assetmemo.bio/drug/bl-m11d1#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07255872-2893@assetmemo.bio
DTSTAMP:20261121T005826Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:BL-M11D1: Phase 2/3 readout est. (NCT07255872)
DESCRIPTION:BL-M11D1\, phase 2/3\, Acute Myeloid Leukemia.\nStudy: A Study 
 of BL-M11D1 in Combination With Cytarabine + Daunorubicin or Venetoclax + 
 Azacitidine in Patients With Acute Myeloid Leukemia\nEstimated primary com
 pletion: December 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/bl-m11d1#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07255872
URL:https://assetmemo.bio/drug/bl-m11d1#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07591168-2893@assetmemo.bio
DTSTAMP:20261121T005826Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:BL-M11D1: Phase 1/2 readout est. (NCT07591168)
DESCRIPTION:BL-M11D1\, phase 1/2.\nStudy: A Study of BL-M11D1 in Patients W
 ith Relapsed/Refractory Myelodysplastic Syndromes\nEstimated primary compl
 etion: December 2028. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /bl-m11d1#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07591168
URL:https://assetmemo.bio/drug/bl-m11d1#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
